|From: SunTzu772 (Rep: 1272)||Date: 01/16/2020 18:42|
|Forum: Wall Street Pit - Msg #2811729 - List DMTK msgs ||Thread #674117356 (Rec: 5) |
|DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay => First coverage contract for the PLA the soon to be new SOC in Skin cancer detection -|
January 16, 2020 5:45pm
DermTech, Inc. (NASDAQ:DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has contracted with a regional health plan to make DermTech's gene expression based Pigmented Lesion Assay ("PLA") for the early detection of melanoma available to the regional health plan's commercial and Medicare Advantage membership. This is the first contract with this health plan that provides coverage for the PLA.
DermTech's PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value ("NPV"), meaning there is a less than 1% chance of the PLA missing a melanoma when administered properly.
"We are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our PLA test offers significant benefits in early melanoma detection and reduced biopsies of benign lesions while also reducing costs to the healthcare system," said Dan Visage, Senior Vice President of Payor Access.
------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.